Avidian Wealth Solutions LLC Has $1.72 Million Position in Eli Lilly and Company (NYSE:LLY)

Avidian Wealth Solutions LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 4.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,944 shares of the company’s stock after acquiring an additional 116 shares during the period. Avidian Wealth Solutions LLC’s holdings in Eli Lilly and Company were worth $1,716,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Lipe & Dalton acquired a new position in Eli Lilly and Company in the 4th quarter valued at approximately $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the 3rd quarter worth $27,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the 3rd quarter worth about $36,000. Family CFO Inc bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $40,000. Finally, O Brien Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after buying an additional 31 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the topic of several analyst reports. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday. Bank of America upped their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Morgan Stanley lifted their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, Wells Fargo & Company upped their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Stock Down 2.8 %

NYSE LLY traded down $20.94 during trading hours on Friday, hitting $734.97. The company’s stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The company has a market capitalization of $698.52 billion, a PE ratio of 108.24, a price-to-earnings-growth ratio of 1.46 and a beta of 0.37. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78. The company’s 50-day simple moving average is $761.06 and its two-hundred day simple moving average is $672.28.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.62 earnings per share. Research analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.